| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1922 | Normal saline Wiki | 0.45 |
| drug675 | Clazakizumab Wiki | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004211 | Disseminated Intravascular Coagulation NIH | 0.50 |
| D020141 | Hemostatic Disorders NIH | 0.27 |
| D001778 | Blood Coagulation Disorders NIH | 0.27 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0005521 | Disseminated intravascular coagulation HPO | 0.50 |
| HP:0001928 | Abnormality of coagulation HPO | 0.27 |
There is one clinical trial.
This study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.
Description: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: Within 24 hours of admission to the hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: 48 to 72 hours after transfer to ICUDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: 1 to 24 hours prior to discharge from hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: Upon arrival at hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: 48 to 72 hours after transfer to ICUDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: 1 to 24 hours prior to discharge from hospital